Published on 29/11/2025

CPV Tailoring for ATMP: Signals and Windows

In the evolving landscape of biologics and advanced therapy medicinal products (ATMPs), effective process validation is critical for ensuring the safety and efficacy of therapeutic products. This tutorial provides practical guidance on Process Performance Qualification (PPQ) and Continuous Process Verification (CPV) tailored specifically for ATMPs. With a focus on regulatory expectations from authorities such as the US FDA, EMA, and MHRA, this guide delves into strategies for managing process complexity, including aspects of viral clearance validation and stringent aseptic controls as outlined in ICH Q5A(R2).

Understanding the Fundamentals of PPQ and CPV for ATMPs

Process Performance Qualification (PPQ) and Continuous Process Verification (CPV) are essential components of a robust quality management system within the context of cGMP for ATMPs. Effective implementation of these methodologies ensures that manufacturing processes consistently produce products that meet predetermined specifications for quality, safety, and efficacy.

PPQ: Definition and Purpose

Process Performance Qualification is a critical stage in the validation lifecycle that confirms the manufacturing process can operate within defined limits and produce a consistent product. This involves a series of critical steps and documentation to verify that the process will function as intended during full-scale manufacturing.

CPV: Definition and Purpose

Continuous Process Verification, on the other hand, is a concept that evolves beyond one-time validation. CPV involves ongoing monitoring and evaluation of the manufacturing process and product data to ensure consistent performance. This means integrating data-driven approaches in real-time to proactively identify deviations that could affect product quality.

The implementation of both PPQ and CPV requires understanding critical quality attributes (CQAs) unique to ATMPs, such as potency, identity, purity, and stability. In this context, the tailing of processes to address specific characteristics of complex product profiles is crucial.

Regulatory Framework: Compliance and Guidelines

To align PPQ and CPV activities for ATMPs, it is essential to be aware of the relevant regulatory guidelines. The FDA’s guidance on process validation emphasizes a lifecycle approach, which is particularly relevant for biologics production. This guidance allows for flexibility in responding to new information and issues arising from clinical data or production changes.

Internationally, the European Medicines Agency (EMA) has also provided a framework for manufacturing ATMPs, which outlines specific requirements for product quality and testing. Understanding the nuances between FDA and EMA regulations is paramount for companies operating in multiple jurisdictions.

Furthermore, regulatory bodies place significant emphasis on demonstrating product sterility, purity, and consistency through rigorous viral clearance validation protocols. Implementing a strategy that encompasses viral clearance methodology, such as spiking studies, is essential to mitigate risks associated with contamination during manufacturing processes.

Viral Clearance Validation: A Crucial Component

Viral clearance validation is an integral part of the validation process for ATMPs, designed to demonstrate that the manufacturing process can effectively remove or inactivate potential viral contaminants. This is crucial for ensuring patient safety.

In the context of ATMPs, viral clearance validation typically involves the following components:

• Risk Assessment: The first step in developing an effective viral clearance strategy involves identifying potential viral risks associated with raw materials, cell lines, and process equipment.
• Spiking Studies: Conducting spiking studies, where known quantities of viral particles are introduced into the process, allows manufacturers to evaluate the efficacy of the viral clearance steps undertaken.
• Recovery Studies: These studies assess the percentage of viral particles that are successfully recovered following the viral clearance step.
• Documenting Compliance: It is imperative to document each aspect of the viral clearance process comprehensively for regulatory compliance.

The validation of these steps should account for the use of closed systems and single-use systems, which have become prevalent in ATMP manufacturing due to their ability to prevent contamination.

Aseptic Processing and Controls: Aligning with Annex 1 Requirements

The complexities of aseptic processing require that manufacturers adhere to stringent production controls as outlined in Annex 1 guidelines issued by the European Medicines Agency. Aseptic manufacturing environments for ATMPs must ensure sterility and product integrity, as any deviation can lead to catastrophic results.

Closed Systems vs. Single-Use Systems

In the realm of aseptic processing, closed systems and single-use systems offer different advantages. Closed systems minimize exposure to ambient environments, thereby reducing contamination risk. On the other hand, single-use systems eliminate the need for cleaning and validation of reusable equipment, streamlining operations and enhancing efficiency.

Implementing these systems requires a comprehensive risk assessment to ensure adequate controls are in place. The combination of these methodologies is paramount for enhancing the safety profile of ATMPs.

Implementation of Aseptic Controls

Effective implementation of aseptic controls includes:

• Environmental Monitoring: Regular monitoring of the manufacturing environment to identify any microbial contamination risks.
• Personnel Training: Continuous educational programs on aseptic techniques for personnel to minimize risks associated with human factors.
• Process Control and Monitoring: Utilizing advanced technology for real-time monitoring of process parameters that influence sterility.

Integration of Potency and Identity CQAs

In ATMP manufacturing, the critical quality attributes (CQAs) related to potency and identity must be carefully defined and monitored. Ensuring that product specifications align with the regulatory expectations of both the FDA and EMA is crucial for regulatory success.

Defining Potency and Identity

Potency refers to the therapeutic effect of the biologic product, while identity ensures that the product is what it claims to be — both are paramount to the efficacy of ATMPs. Establishing robust analytical methods to validate the potency and identity helps in meeting the stringent validation expectations set forth by various regulatory bodies, including the WHO.

Chain of Identity and Custody

Maintaining a documented chain of identity (COI) and chain of custody (COC) is vital in managing product traceability, particularly in multi-step manufacturing processes. This involves thorough record-keeping and auditing practices, ensuring that every step from raw material acquisition through to batch release is accounted for and aligned with regulatory requirements.

Monitoring and Continuous Improvement Practices

Implementation of a CPV strategy facilitates ongoing compliance with regulatory standards and enhances product quality by incorporating real-time monitoring, data analytics, and corrective actions. As part of the CPV, it is essential to establish key performance indicators (KPIs) and trending analyses of manufacturing processes.

Data Integration and Analytics

Integration of production data using advanced analytics tools enables identifying trends that offer insights into process stability and performance consistency. Ongoing assessments provide opportunities for continuous improvement, crucial for maintaining product quality in line with evolving regulatory expectations.

Feedback Mechanisms

Establishing effective feedback loops within the manufacturing process allows organizations to respond swiftly to quality deviations and implement corrective actions in a timely manner. Training staff to recognize and address potential issues as they arise aids in sustaining high-quality standards.

Conclusion: Navigating the Challenges of PPQ and CPV for ATMPs

The validation landscape for Advanced Therapy Medicinal Products is multifaceted and requires a comprehensive understanding of both scientific and regulatory factors. By implementing tailored PPQ and CPV strategies that align with current regulatory expectations, industry professionals can ensure the safety, efficacy, and quality of ATMPs.

This step-by-step guide emphasizes the importance of careful planning and execution of viral clearance validation, aseptic control measures, management of potency and identity CQAs, and establishing robust monitoring and continuous improvement practices. Successfully navigating these elements will support manufacturers in their commitment to delivering safe and effective therapeutic products which comply with global standards.